Puma Biotechnology (PBYI)
(Real Time Quote from BATS)
$3.72 USD
+0.06 (1.64%)
Updated Jul 22, 2024 02:46 PM ET
4-Sell of 5 4
A Value A Growth C Momentum A VGM
Company Summary
Los Angeles, CA-based Puma Biotechnology, Inc. is a small cancer biotech whose only marketed product, Nerlynx (neratinib) is approved for the treatment of early stage HER2-positive breast cancer in patients who have been previously treated with Roche’s Herceptin-based adjuvant therapy. Nerlynx in combination with Roche’s Xeloda was approved by the Food and Drug Administration (FDA) for third-line HER2-positive metastatic breast cancer in February 2020. Puma Biotechnology has also received additional approvals for using Nerlynx in the extended adjuvant population.
Nerlynx recorded sales worth $203.1 million in 2023, up 1.6% ...
Company Summary
Los Angeles, CA-based Puma Biotechnology, Inc. is a small cancer biotech whose only marketed product, Nerlynx (neratinib) is approved for the treatment of early stage HER2-positive breast cancer in patients who have been previously treated with Roche’s Herceptin-based adjuvant therapy. Nerlynx in combination with Roche’s Xeloda was approved by the Food and Drug Administration (FDA) for third-line HER2-positive metastatic breast cancer in February 2020. Puma Biotechnology has also received additional approvals for using Nerlynx in the extended adjuvant population.
Nerlynx recorded sales worth $203.1 million in 2023, up 1.6% year over year.
Puma Biotechnology markets Nerlynx in the United States and has several sub-licenses in various regions outside the United States to commercialize Nerlynx in some international markets.
In September 2022, Puma Biotechnology in-licensed global development and commercialization rights to alisertib, an aurora kinase A inhibitor, from Japan’s Takeda.
Puma Biotechnology plans to develop alisertib for the treatment of various types of cancer indications, including hormone receptor-positive breast cancer as well as small-cell lung cancer (SCLC).
If alisertib is successfully developed for the mentioned indications, it could enhance Puma Biotechnology’s position in the target market for anti-cancer drugs.
The company recorded total revenues of $235.6 million for 2023 compared with $228 million reported in 2022.
General Information
Puma Biotechnology, Inc
10880 WILSHIRE BOULEVARD SUITE 2150
LOS ANGELES, CA 90024
Phone: 424-248-6500
Fax: 424-248-6501
Web: http://www.pumabiotechnology.com
Email: ir@pumabiotechnology.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Earnings Date | 8/1/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -0.08 |
Current Year EPS Consensus Estimate | 0.40 |
Estimated Long-Term EPS Growth Rate | NA |
Earnings Date | 8/1/2024 |
Price and Volume Information
Zacks Rank | ![]() |
Yesterday's Close | 3.66 |
52 Week High | 7.73 |
52 Week Low | 2.13 |
Beta | 1.09 |
20 Day Moving Average | 700,356.19 |
Target Price Consensus | 5.50 |
4 Week | 22.41 |
12 Week | -27.09 |
YTD | -15.47 |
4 Week | 21.51 |
12 Week | -32.46 |
YTD | -26.76 |
Shares Outstanding (millions) | 48.24 |
Market Capitalization (millions) | 176.55 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | 0.00 |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 9.07 |
Trailing 12 Months | 6.91 |
PEG Ratio | NA |
vs. Previous Year | -433.33% |
vs. Previous Quarter | -138.46% |
vs. Previous Year | -17.05% |
vs. Previous Quarter | -39.34% |
Price/Book | 3.46 |
Price/Cash Flow | 5.26 |
Price / Sales | 0.78 |
6/30/24 | NA |
3/31/24 | 35.49 |
12/31/23 | 58.21 |
6/30/24 | NA |
3/31/24 | 7.26 |
12/31/23 | 10.40 |
6/30/24 | NA |
3/31/24 | 1.46 |
12/31/23 | 1.57 |
6/30/24 | NA |
3/31/24 | 1.38 |
12/31/23 | 1.50 |
6/30/24 | NA |
3/31/24 | 6.79 |
12/31/23 | 9.16 |
6/30/24 | NA |
3/31/24 | 6.79 |
12/31/23 | 9.16 |
6/30/24 | NA |
3/31/24 | 7.29 |
12/31/23 | 9.62 |
6/30/24 | NA |
3/31/24 | 1.06 |
12/31/23 | 1.12 |
6/30/24 | NA |
3/31/24 | 8.76 |
12/31/23 | 10.33 |
6/30/24 | NA |
3/31/24 | 1.07 |
12/31/23 | 1.23 |
6/30/24 | NA |
3/31/24 | 51.76 |
12/31/23 | 55.13 |